AptarGroup (NYSE:ATR) used its annual shareholder meeting on May 9, 2026, to announce a planned chief executive transition, confirm shareholder approval of all ballot items, and provide a detailed update on 2025 financial performance and early 2026 results. The meeting, conducted virtually, underscored the company’s steady leadership pipeline and financial discipline.
CEO Succession Plan Announced
President and Chief Executive Officer Stephan Tanda told shareholders that he plans to retire after nearly a decade in the role. Gael Touya, currently president of Aptar Pharma and a company veteran with more than 30 years of experience, will assume the positions of president and CEO on September 1, 2026. Tanda will remain in his current role until the transition date and then serve as an adviser through the end of the year to ensure a smooth handoff. He also expects to retire from the board at year-end, while the board plans to appoint Touya as a director effective September 1, 2026.
Also read: CareTrust REIT Reports Record Q1 Investment Activity, Raises Full-Year Guidance
Touya expressed gratitude for the opportunity, calling Aptar his “professional home” for more than three decades and thanking Tanda for his leadership. The succession plan reflects a deliberate, internally developed transition strategy common among well-governed industrial firms.
Shareholder Votes and Governance
Irene Hudson, executive vice president, chief legal officer and secretary, confirmed that a quorum was present at the virtual-only meeting. No shareholder nominations or other motions were received, leaving only the matters listed in the annual meeting notice for consideration. Based on preliminary vote counts, shareholders elected four directors to serve until the 2029 annual meeting: George L. Fotiades, Candace Matthews, B. Craig Owens, and Julie Xing. Shareholders also approved, on an advisory basis, Aptar’s executive compensation and ratified PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for 2026. No shareholder questions were submitted during the Q&A portion, according to Mary Scafidas, senior vice president of investor relations and communications.
2025 Financial Performance
Following the formal meeting, Tanda reviewed the company’s business performance. For 2025, reported sales increased 5% to $3.8 billion from $3.6 billion in the prior year. Core sales rose 2%, reflecting steady demand across key product categories. The company returned $486 million to shareholders through share repurchases and dividends during the year. Tanda also noted that 2025 marked Aptar’s 32nd consecutive year of paying an annually increasing dividend, a strong signal of financial stability and shareholder commitment.
Segment Highlights
The Pharma segment led growth, with sales rising 6% to $1.74 billion, driven by strong demand for emergency medicine and central nervous system products, as well as higher royalties. Tanda highlighted a growing number of systemic nasal drug delivery projects and increased participation in injectable projects, including those for GLP-1 and NX-1. The Beauty segment reported a 7% sales increase to $1.31 billion, with currency and acquisitions contributing positively. The Closures segment grew 2% to $730.3 million, including a currency benefit and slight core sales growth.
Capital Allocation and 2026 Outlook
Tanda emphasized the company’s focus on investing in higher-returning, faster-growing businesses, particularly Pharma, while maintaining a commitment to returning capital to shareholders. Over the past five years, Aptar has returned $1.2 billion to shareholders through dividends and share repurchases. For the first quarter of 2026, reported sales increased 11%, though core sales, adjusted for currency effects and acquisitions, were flat compared with the prior year. The company’s long-term financial targets remain unchanged, including an adjusted EBITDA margin target of 21% to 23% and an overall core sales growth target of 4% to 7%. Tanda said the company intends to continue executing a productivity roadmap aimed at addressing short-term headwinds and improving efficiency across operations, supply chains, and selling, general and administrative expenses.
Why This Matters
The CEO succession at AptarGroup is significant for investors and industry observers because it represents a planned, orderly transition at a company with a strong track record of dividend growth and consistent financial performance. The appointment of an internal candidate with deep industry experience signals strategic continuity, particularly in the high-growth Pharma segment. The 2025 results and 2026 outlook reinforce Aptar’s position as a reliable player in the packaging and drug-delivery space, with a balanced approach to growth and shareholder returns.
Conclusion
AptarGroup’s annual meeting provided a clear picture of a company executing a well-defined leadership transition while maintaining solid financial performance. With 2025 sales up 5%, a 32-year dividend growth streak, and a clear strategic focus on Pharma and efficiency, Aptar appears well-positioned for sustained performance. The transition to Gael Touya, a company veteran, suggests minimal disruption and continued focus on the company’s long-term goals.
FAQs
Q1: When will Gael Touya become CEO of AptarGroup?
A1: Gael Touya will assume the role of president and CEO on September 1, 2026. Stephan Tanda will serve as an adviser through the end of the year.
Q2: How did AptarGroup perform in 2025?
A2: AptarGroup reported a 5% increase in sales to $3.8 billion, with core sales up 2%. The company returned $486 million to shareholders through dividends and buybacks.
Q3: What are AptarGroup’s long-term financial targets?
A3: The company targets an adjusted EBITDA margin of 21% to 23% and overall core sales growth of 4% to 7% annually.
